| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 1995 American Heart Association, Inc.
Articles |
Upregulation of Cardiac Angiotensin II AT1 Receptors in Congenital Cardiomyopathic Hamsters
From the Department of Pharmacology (C.L., Y.M., S.M.), Faculty of Medicine, Université de Montréal (Canada), and Centre de Recherche (S.M.), Hôtel-Dieu de Montréal (Canada).
Correspondence to Chantal Lambert, BPharm., PhD, CP 6128, Succursale Centre-Ville, Montréal, H3C 3J7, Canada.
Abstract Angiotensin II (Ang II) is a growth factor that stimulates protein synthesis and induces cellular hypertrophy in cardiac myocytes. To gain insight into the role of Ang II in cardiac hypertrophy, we examined the expression and subtype distribution of Ang II receptors in the ventricles of embryonic and of 25- to 350-day-old inbred control and cardiomyopathic (CHF 146) hamsters. Studies were also performed with heterozygous (cardiomyopathicxcontrol) animals. Compared with the control hamsters, cardiomyopathic hamsters presented decreased body weights and increased ratios of ventricular weight to body weight in every adult group studied. Typical histological lesions appeared in the left ventricle of cardiomyopathic animals around 70 to 75 days, and their severity increased with time. Radioligand binding studies with cardiac ventricular membranes indicated that iodinated [Sar1,Ile8]Ang II (sarile) binds to a homogeneous population of sites in membranes derived from adult normal and cardiomyopathic animals. Competition curves using specific receptor subtype antagonists revealed that 125I-sarile binding sites were exclusively of the AT1 subtype in both groups of animals. Importantly, the density of AT1 receptors was found to be significantly increased (90% augmentation at 70 to 75 days) in the ventricles of cardiomyopathic hamsters. This augmented expression was observed in all adult groups and was already present at 25 days, when no histological lesions were visible. The affinity of the receptor for losartan did not vary significantly between adult normal and cardiomyopathic animals (mean Kd, 19.6 and 16.7 nmol/L, respectively). No significant differences were observed in the total expression of Ang II receptors and in the proportion of AT1 and AT2 subtypes between the two groups of embryonic hearts. Heterozygous animals expressed an intermediate level of AT1 receptor binding activity in their ventricles. Together, these results suggest that Ang II acting through the AT1 receptor may play a critical role in the development and/or maintenance of cardiac hypertrophy.
Key Words: cardiomyopathic hamsters • angiotensin receptors • losartan • hypertrophy • heart
This article has been cited by other articles:
 |
|
 |
|
  D. M. Browe and C. M. Baumgarten Angiotensin II (AT1) Receptors and NADPH Oxidase Regulate Cl- Current Elicited by {beta}1 Integrin Stretch in Rabbit Ventricular Myocytes J. Gen. Physiol., August 30, 2004; 124(3): 273 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Schultz, X. Su, C.-C. Wei, S. P. Bishop, P. Powell, G. H. Hankes, A. R. Dillon, P. Rynders, F. G. Spinale, G. Walcott, et al. Downregulation of ANG II receptor is associated with compensated pressure-overload hypertrophy in the young dog Am J Physiol Heart Circ Physiol, February 1, 2002; 282(2): H749 - H756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Rouleau, G. Kapuku, S. Pelletier, H. Gosselin, A. Adam, C. Gagnon, C. Lambert, and S. Meloche Cardioprotective Effects of Ramipril and Losartan in Right Ventricular Pressure Overload in the Rabbit: Importance of Kinins and Influence on Angiotensin II Type 1 Receptor Signaling Pathway Circulation, August 21, 2001; 104(8): 939 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ozono, T. Matsumoto, T. Shingu, T. Oshima, Y. Teranishi, M. Kambe, H. Matsuura, G. Kajiyama, Z.-Q. Wang, A. F. Moore, et al. Expression and localization of angiotensin subtype receptor proteins in the hypertensive rat heart Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2000; 278(3): R781 - R789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Bastien, A.-V. Juneau, J. Ouellette, and C. Lambert Chronic AT1 receptor blockade and angiotensin-converting enzyme (ACE) inhibition in (CHF 146) cardiomyopathic hamsters: effects on cardiac hypertrophy and survival Cardiovasc Res, July 1, 1999; 43(1): 77 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Matsubara Pathophysiological Role of Angiotensin II Type 2 Receptor in Cardiovascular and Renal Diseases Circ. Res., December 14, 1998; 83(12): 1182 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ikezaki, H. Onyuksel, and I. Rubinstein Liposomal VIP attenuates phenylephrine- and ANG II-induced vasoconstriction in vivo Am J Physiol Regulatory Integrative Comp Physiol, August 1, 1998; 275(2): R588 - R595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ohkubo, H. Matsubara, Y. Nozawa, Y. Mori, S. Murasawa, K. Kijima, K. Maruyama, H. Masaki, Y. Tsutumi, Y. Shibazaki, et al. Angiotensin Type 2 Receptors Are Reexpressed by Cardiac Fibroblasts From Failing Myopathic Hamster Hearts and Inhibit Cell Growth and Fibrillar Collagen Metabolism Circulation, December 2, 1997; 96(11): 3954 - 3962. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Giasson, M. J. Servant, and S. Meloche Cyclic AMP-mediated Inhibition of Angiotensin II-induced Protein Synthesis Is Associated with Suppression of Tyrosine Phosphorylation Signaling in Vascular Smooth Muscle Cells J. Biol. Chem., October 24, 1997; 272(43): 26879 - 26886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Regitz-Zagrosek, J. Fielitz, R Dreysse, A. G Hildebrandt, and E. Fleck Angiotensin receptor type 1 mRNA in human right ventricular endomyocardial biopsies: downregulation in heart failure Cardiovasc Res, July 1, 1997; 35(1): 99 - 105. [Abstract] [Full Text] [PDF]
|
|